Juvena Therapeutics
Redwood City, US · Founded 2017 · Delaware corporation · 42 employees on LinkedIn · 11 known investors
Find your way into Juvena Therapeutics
967 people in our graph share verified history with the Juvena Therapeutics team — schools, employers, funds. One of them is your warm intro.
Javier Solterounlockedknows Dr. Hanadie Yousef · together at Carnegie Mellon University (overlapped)
×2knows the team · via University of Wisconsin-Madison
×4knows the team · via The University of Texas at Austin
knows the team · via UC Berkeley
knows the team · via Harvard Medical School
knows the team · via Regeneron Pharmaceuticals, Inc.
Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.
Founders & leadership
Juvena Therapeutics was founded in 2017 by Jeremy O'Connell, PhD, Hanadie Yousef, PhD, Jeremy O'Connell, and Dr. Hanadie Yousef.
JO
Jeremy O'Connell, PhDChief Scientific Officer and Co-Founder
HY
Hanadie Yousef, PhDExecutive Advisor and Co-Founder
JO
Jeremy O'ConnellinCSO and Co-founderHe holds a PhD in protein biochemistry and brings 15 years of experience in mass spectrometry-based proteomics, cell and systems biology, and various imaging techniques.
DH
Dr. Hanadie YousefinFounder, Board Director and Executive AdvisorDr. Hanadie Yousef founded Juvena Therapeutics in 2017, serving as CEO, CFO, and Board Chair through 2025 before continuing as Board Director and Executive Advisor; the company develops biologics from human secreted proteins to treat aging-related muscle and metabolic disorders. She holds a B.S. from Carnegie Mellon and a PhD from UC Berkeley, completed postdoctoral training at Stanford School of Medicine, and also runs the advisory firm Luminous BioStrategies.
Board
BH
LL
Laura Lande-DinerinBoard Member
AA
Ayman AlAbdallahBoard director
SJ
Steven JamesinMember Board of Directors
SJ
Stephen JuelsgaardinMember Board Of Directors
CK
Christopher KirkBoard director
Investors · 11
Alumni VenturesManchester · $100K – $10M
Bascom VenturesBoston
Bison VenturesSeattle
CompoundNew York · $400K – $1.5M
Harmonix FundLa Quinta
Horizons VenturesHong Kong · $1M – $110M
Manta Ray VenturesLondon
Open Field CapitalNew York
Plum Alley InvestmentsNew York · $500K – $1.5M
Transform Capital ManagementSan Francisco
BoxOne VenturesreportedMontréal · $500K
Reported raises · per SEC filings
Form D private placements$34.8M disclosed across 2 rounds · 2018–2025
▶$30.5MraisedJul 2025 · 12 investors · Other TechnologyRule 506(b)
▶$30.5MraisedJul 2025 · 12 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Steven JamesDirector
- Ben HemaniDirector
- Stephen JuelsgaardDirector
- Hanadie YousefExecutive Officer, Director
- Laura Lande-DinerDirector
- Christopher KirkDirector
- Ayman AlAbdallahDirector
- Jeremy O'ConnellDirector
- Offering amount
- $41M
- Amount sold
- $30.5M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedFeb 2018 · 23 investors · Other TechnologyRule 506(b)
▶$4.3MraisedFeb 2018 · 23 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Hanadie YousefExecutive Officer, Director
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Juvena Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlap
IQVIA20 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Juvena Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $254.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Regenerative Medicine Startup Funding (2026) – New Market Pitchnewmarketpitch.com · Jul 2026Frequently asked questions
- What does Juvena Therapeutics do?
- Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.
- Who founded Juvena Therapeutics?
- Juvena Therapeutics was founded by Jeremy O'Connell, PhD, Hanadie Yousef, PhD, Jeremy O'Connell, Dr. Hanadie Yousef in 2017.
- Who are Juvena Therapeutics's investors?
- Juvena Therapeutics's investors include Alumni Ventures, Bascom Ventures, Bison Ventures, Compound, Harmonix Fund, Horizons Ventures, Manta Ray Ventures, Open Field Capital and 3 more.
- How much funding has Juvena Therapeutics raised?
- Juvena Therapeutics has disclosed $34.8M raised across 2 rounds.
- Where is Juvena Therapeutics headquartered?
- Juvena Therapeutics is headquartered in Redwood City, US.